Rose Lab Inc.

Rose Lab Inc. , based in South Korea, is engaged in providing innovative biotechnological solutions aimed at enhancing human beauty and well-being through advanced research and development. Founded in 2016 in Seoul, South Korea, Rose Lab Inc. develops biotechnological products designed to improve skin health and mitigate aging effects.

The company has successfully raised KRW 10 billion in its latest funding round from Reverent Partners and Shinhan Capital as part of its growth strategy. To date, Rose Lab Inc. has completed five funding deals, with the most recent occurring on August 21, 2025, focusing on expanding its product offerings and market presence. Rose Lab Inc.

specializes in advanced biotechnological solutions that promote human beauty and well-being. Its core offerings include biostimulators made from polymer compounds that enhance collagen production, targeting skin aging. The company caters to individual consumers and medical professionals in South Korea and other Asian markets, supplying beauty clinics and dermatology practices with effective skin care technologies. Rose Lab Inc.

operates on a business-to-business (B2B) model, supplying its biostimulator products directly to healthcare providers and beauty establishments. Revenue is generated through partnerships with clinics and distributors that integrate Rose Lab's offerings into their services, underpinned by supply agreements and service contracts. Pricing aligns with market standards for premium cosmetic and medical devices, reflecting the proprietary nature of its anti-aging technologies. The company plans to design and launch new biotechnological products aimed at expanding its market reach.

Specific target markets for expansion include additional regions in Asia, with efforts to commence by late 2026, focusing on increasing brand presence and distribution channels. The recent funding will be pivotal in facilitating product development and market entry strategies.